Skip to content

Main Navigation

Fennec Pharmaceuticals
Fennec Pharmaceuticals
  • For Families
    • Advocacy Groups
    • Family Stories
    • Named Patient Access
  • Product
  • Science
    • Cisplatin-Induced Hearing Loss
  • About Us
    • Our Mission
    • Our Team
  • Investors
    • Corporate Profile
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
  • Contact Us
  • For Families
    • Advocacy Groups
    • Family Stories
    • Named Patient Access
  • Product
  • Science
    • Cisplatin-Induced Hearing Loss
  • About Us
    • Our Mission
    • Our Team
  • Investors
    • Corporate Profile
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
  • Contact Us

Helping kids hear the future

Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.

Discover what we stand for
Explore what we’re focused on
See product details

Latest News

  • February 1, 2024FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
  • December 5, 2023Fennec Announces Incremental $5 Million Investment from Petrichor
  • November 9, 2023Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
See More

Resources

For Investors
For Families

You are now leaving Fennec Pharmaceuticals to access a product-specific website intended for US citizens only.

Please visit us again soon!

Continue

Fennec® is a registered trademark of Fennec Pharmaceuticals Inc.
©2024 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1538-v4 3/24

  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Careers
  • Sitemap